Abstract
Under physiological conditions, the trans-presentation of interleukin-15 (IL-15) by the IL-15 receptor alpha on the cell surface allows to confine and tune the IL-15-mediated immune responses. Therefore, targeting strategies that mimic this situation at the tumor sites appear especially promising for anticancer immunotherapy.
Users
Please
log in to take part in the discussion (add own reviews or comments).